0.43USD
22.81 MUSD
96.74 MUSD
36.22 M
About Spero Therapeutics, Inc.
Sector
Industry
CEO
Satyavrat Shukla
Website
Headquarters
Cambridge
Employees (FY)
46
Founded
2013
ISIN
US84833T1034
FIGI
BBG00HXSJ1R2
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
SPRO Final 3rd Testing SuccessfulI bought this stock too early and watch it get clobbered. Then they announced their drug final 3rd stage testing was successful. This company is a $30 stock but they still have to raise money and go to market. BUT this guarantees they will be successful.
Flag Decision Shortly SPROThis pattern build over many months when broken up or down will signal the future direction. I am buying with stop at 11.60 looking for upside break out in the next month.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SPRO is 1.47 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Spero Therapeutics, Inc. stocks are traded under the ticker SPRO.
Spero Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
SPRO stock is 4.16% volatile and has beta coefficient of 1.14. Check out the list of the most volatile stocks — is Spero Therapeutics, Inc. there?
One year price forecast for Spero Therapeutics, Inc. has a max estimate of 8.00 USD and a min estimate of 7.00 USD.
SPRO earnings for the last quarter are −0.06 USD per share, whereas the estimation was −0.03 USD resulting in a −100.00% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about Spero Therapeutics, Inc. earnings.
Spero Therapeutics, Inc. revenue for the last quarter amounts to 25.47 M USD despite the estimated figure of 14.97 M USD. In the next quarter revenue is expected to reach 18.63 M USD.
Yes, you can track Spero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
SPRO stock has fallen by 14.04% compared to the previous week, the month change is a 16.00% fall, over the last year Spero Therapeutics, Inc. has showed a 15.03% decrease.
SPRO net income for the last quarter is 51.19 M USD, while the quarter before that showed −3.21 M USD of net income which accounts for 1.70 K% change. Track more Spero Therapeutics, Inc. financial stats to get the full picture.
Today Spero Therapeutics, Inc. has the market capitalization of 79.19 M, it has decreased by 6.67% over the last week.
No, SPRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SPRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Spero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 46.00 employees. See our rating of the largest employees — is Spero Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Spero Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Spero Therapeutics, Inc. stock shows the sell signal. See more of Spero Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Spero Therapeutics, Inc. future price: according to them, SPRO price has a max estimate of 8.00 USD and a min estimate of 7.00 USD. Read a more detailed Spero Therapeutics, Inc. forecast: see what analysts think of Spero Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Spero Therapeutics, Inc. EBITDA is 20.59 M USD, and current EBITDA margin is 20.79%. See more stats in Spero Therapeutics, Inc. financial statements.